1. India Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: other
Zenith Healthcare Limited

Zenith Healthcare Limited

BBSE:ZENITHHE
3.11
INR
+0.09
(+2.98%)
0.03EPS
104.72P/E
164.98MMarket Cap
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
2026 Y
TTM
Revenue per Share
0.61
0.68
0.64
0.89
1.77
1.83
2.23
2.56
4.16
2.44
2.69
2.11
1.94
1.98
Basic EPS, GAAP
-0.05
-0.04
-0.06
-0.03
0.05
0.03
0.11
0.08
0.06
0.01
0.04
0.01
- -
0.03
Free Cash Flow per Basic Share
-0.16
-0.03
0.02
0.02
0.05
-0.02
0.27
-0.31
0.2
-0.18
0.3
0.03
-0.18
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
1.13
1.09
1.03
1
1.05
1.08
1.19
1.27
1.33
1.35
1.37
1.38
1.38
- -
Tangible Book Value per Share
1.12
1.09
1.03
1
1.05
1.08
1.19
1.27
1.33
1.35
1.37
1.37
1.38
- -
Basic Weighted Avg Shares
54
54
54
54
54
54
54
54
54
54
54
54
54
55
Sales/Revenue/Turnover
33
36
35
48
95
98
120
137
224
131
145
113
104
108
Operating Margin (%)
-15.23
-11.02
-17
-4.78
3.04
-0.23
2.52
-1.44
0.62
-1.77
3.99
2.04
-1.99
-0.81
Depreciation Expense
2
4
4
3
3
2
3
3
4
3
2
2
3
3
Net Income, GAAP
-3
-2
-3
-2
3
1
6
4
3
1
2
1
- -
2
Effective Tax Rate (%)
- -
- -
- -
- -
31.64
17.52
3.3
21.18
48.75
34.12
26.21
76
67.5
28.35
Profit Margin (%)
-8.27
-6.66
-8.96
-3.17
2.87
1.39
4.72
3.2
1.39
0.59
1.41
0.59
0.05
1.48
Working Capital
31
30
27
26
32
36
40
45
50
51
49
46
39
- -
LT Debt
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Total Equity
61
59
55
54
57
58
64
68
72
72
73
74
74
- -
Return on Invested Capital (%)
- -
- -
- -
- -
3.58
-0.32
4.72
-2.32
1.03
-2.11
0.27
0.08
-2.1
- -
Return on Capital (%)
- -
- -
- -
- -
4.96
2.38
9.27
6.65
4.44
1.08
2.79
0.95
0.11
- -
Return on Common Equity (%)
-4.37
-4.06
-5.45
-2.78
4.95
2.38
9.27
6.64
4.44
1.08
2.79
0.91
0.07
- -

Capital Structure

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
54
54
54
Market Capitalization
180
130
165

Working Capital

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
Total Current Assets
- -
75
- -
Cash, Cash Equivalents & STI
- -
7
- -
Accounts Receivable, Net
- -
21
- -
Inventories
- -
29
- -
Total Current Liabilities
- -
36
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
3.03%
1.65%
0.24%
Free Cash Flow
-307.27%
-280.68%
-689.15%
Net Income, GAAP
-19.11%
-20.45%
-92.39%
Sales/Revenue/Turnover
17.87%
0.4%
-7.92%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
26
30
23
34
113
2026
32
23
25
26
104
2027
34
- -
- -
- -
- -

Quarterly Earnings Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
0.03
0.02
-0.05
0.02
0.01
2026
- -
0.03
0.04
-0.06
- -
2027
0.03
- -
- -
- -
- -

Quarterly Dividends Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
2027
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Mahendra Chatrabhuj Raycha
Full Time Employees
42
Sector
Health technology
Industry
Pharmaceuticals: other
Address
504, Iscon Elegance Ahmedabad GU India 380015
IPO Date
Apr 27, 1995
Website
zenithhealthcare.com
Similar Companies
Cipla Ltd (NSE:CIPLA)
Aurobindo Pharma Ltd (NSE:AUROPHARMA)
Lupin Limited (NSE:LUPIN)
Granules India Limited (NSE:GRANULES)
Revolution Medicines, Inc. (NASDAQ:RVMD)
Egyptian International Pharmaceutical Industries Co. (EGX:PHAR)
Business
Zenith Healthcare Limited manufactures and markets pharmaceutical formulations in India from its WHO-GMP compliant facility in Changodar, Ahmedabad, Gujarat. The company, founded in 1994 and headquartered at 504 Iscon Elegance, Prahladnagar, Ahmedabad, produces tablets including Alprazolam & Propranolol HCL and Pantoprazole Sodium Levosulpiride; capsules such as Vicadol and Mdzime; oral liquids like Azithromycin Dihydrate Suspension, Cofzen Syrup, Domperidone Suspension, Zenoset Syrup and Valprex Syrup; ointments; liquid injectables; and psychotropic products numbering over 110 among its total portfolio of 350 items, with additional offerings in directly compressible granules. It operates domestically across India via marketing and PCD distributorships while exporting to South East Asia including Cambodia, Myanmar, Papua New Guinea and Sri Lanka; Africa encompassing Kenya, Nigeria, Gambia, Zambia, Namibia and Botswana; CIS countries such as Armenia, Georgia and Uzbekistan; Latin and Central America covering Paraguay, Bolivia, Venezuela, Guatemala, Barbados, Jamaica and Bahamas; and GCC nations like Yemen and Turkey, focusing on therapeutic segments including antibiotics, anti-infectives, gastrointestinal, analgesic/anti-inflammatory, cardiovascular, respiratory, ophthalmology, oncology, anti-retroviral, central nervous system, nutrition, genito-urinary and skin care. Recent developments include the launch of a state-of-the-art EU-cGMP accreditable plant expanding capabilities for general tablets, effervescent tablets, capsules, soft gel capsules, sachets and liquid inhalation such as Sevoflurane, alongside routine financial reporting such as audited results for FY 2024-25 showing net profit growth to Rs 0.14 crore in Q2 FY26 and board approvals for ongoing operations.